Electronic Cardiac Rehabilitation (eCardiacRehab) Feasibility Study
Launched by HAUKELAND UNIVERSITY HOSPITAL · Dec 29, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The eCardiacRehab study is looking at a new way to help patients with coronary artery disease recover after heart procedures, specifically using a home-based program that patients can access online. This is important because in Norway, many people who could benefit from cardiac rehabilitation are not participating in traditional programs. The goal of this trial is to make rehabilitation more accessible, especially for older adults, women, and those with other health challenges. Researchers will work with patients and healthcare providers to create and evaluate this program to ensure it meets the needs of those who are often overlooked.
To be eligible for this study, participants need to be adults who speak Norwegian or another Scandinavian language, have had a heart procedure (like angioplasty), live at home with internet access, and agree to take part in the study. However, people with certain serious heart conditions or cognitive impairments that affect their ability to follow the study's instructions may not be able to participate. If chosen for the trial, participants can expect to receive support and resources tailored to help them improve their heart health from the comfort of their own homes. This innovative program aims to provide better care and support for patients, helping them lead healthier lives after their heart procedures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult Norwegian (or Scandinavian) speaking patients (≥ 18 years) who have a Norwegian national identification number,
- • With coronary artery disease after percutaneous coronary intervention
- • Are living at home and have internet available to them
- • Providing signed informed consent
- Exclusion Criteria:
- • Patients with cognitive impairment that may interfere with the ability to comply with the study protocol
- • Severe aortic stenosis
- • Severe arrhythmias
- • Expected lifetime less than one year as determined by study personnel
- • Otherwise clinically unstable
- • Not fully revascularized (awaits percutaneous coronary intervention or coronary artery bypass graft surgery)
- • Inability to comply with the study protocol due to any physical disability, somatic disease, or mental problems as determined by study personnel
About Haukeland University Hospital
Haukeland University Hospital, located in Bergen, Norway, is a leading academic medical center renowned for its commitment to innovative research and high-quality patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in various medical fields to facilitate cutting-edge clinical studies that aim to advance healthcare outcomes. With a multidisciplinary team of healthcare professionals and researchers, Haukeland University Hospital fosters collaboration and knowledge exchange, ensuring that trials are conducted with the highest standards of ethics, safety, and scientific rigor. Its strategic focus on translational research enhances the bridge between laboratory discoveries and real-world applications, contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergen, , Norway
Patients applied
Trial Officials
Tone M Norekvål, PhD
Principal Investigator
Haukeland University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported